Exact Sciences Corporation (NASDAQ:EXAS)‘s stock had its “buy” rating reiterated by equities research analysts at Canaccord Genuity in a research note issued on Tuesday. They currently have a $60.00 price target on the medical research company’s stock, up from their prior price target of $45.00. Canaccord Genuity’s price target would suggest a potential upside of 25.03% from the stock’s previous close.

Other equities analysts have also issued research reports about the company. Vetr raised Exact Sciences Corporation from a “sell” rating to a “hold” rating and set a $36.55 price target on the stock in a research note on Tuesday, July 25th. Roth Capital increased their target price on Exact Sciences Corporation from $40.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday, July 26th. Lake Street Capital increased their target price on Exact Sciences Corporation from $30.00 to $41.00 and gave the stock a “hold” rating in a research note on Wednesday, July 26th. BTIG Research reissued a “buy” rating and set a $45.00 target price (up previously from $35.00) on shares of Exact Sciences Corporation in a research note on Monday, July 17th. Finally, Craig Hallum reissued a “buy” rating and set a $46.00 target price (up previously from $41.00) on shares of Exact Sciences Corporation in a research note on Wednesday, July 26th. Five equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $43.11.

Shares of Exact Sciences Corporation (NASDAQ:EXAS) traded down 0.17% during trading on Tuesday, hitting $47.91. The stock had a trading volume of 169,170 shares. Exact Sciences Corporation has a 12 month low of $13.05 and a 12 month high of $50.65. The stock’s market cap is $5.71 billion. The company’s 50 day moving average price is $42.81 and its 200 day moving average price is $34.86.

Exact Sciences Corporation (NASDAQ:EXAS) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.10. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. The business had revenue of $57.65 million for the quarter, compared to analyst estimates of $47.73 million. Equities research analysts expect that Exact Sciences Corporation will post ($1.18) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at http://www.mareainformativa.com/exact-sciences-corporation-exas-stock-rating-reaffirmed-by-canaccord-genuity/117307/.

In related news, CFO Jeffrey Thomas Elliott sold 5,846 shares of the company’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $39.41, for a total value of $230,390.86. Following the completion of the sale, the chief financial officer now directly owns 19,861 shares of the company’s stock, valued at approximately $782,722.01. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Thomas D. Carey bought 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The stock was purchased at an average cost of $37.71 per share, with a total value of $94,275.00. Following the completion of the transaction, the director now owns 60,858 shares in the company, valued at $2,294,955.18. The disclosure for this purchase can be found here. Over the last three months, insiders sold 237,444 shares of company stock valued at $10,412,421. Insiders own 4.00% of the company’s stock.

A number of institutional investors have recently bought and sold shares of EXAS. Fortaleza Asset Management Inc. acquired a new stake in Exact Sciences Corporation during the 2nd quarter worth approximately $106,000. Krilogy Financial LLC lifted its position in Exact Sciences Corporation by 1,460.0% during the 2nd quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after acquiring an additional 3,650 shares during the period. Northwestern Mutual Wealth Management Co. lifted its position in Exact Sciences Corporation by 17.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after acquiring an additional 600 shares during the period. Financial Architects Inc lifted its position in Exact Sciences Corporation by 90.0% during the 2nd quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock worth $152,000 after acquiring an additional 2,035 shares during the period. Finally, Johnson Financial Group Inc. lifted its position in Exact Sciences Corporation by 25.9% during the 2nd quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock worth $172,000 after acquiring an additional 1,000 shares during the period. 85.23% of the stock is owned by institutional investors.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Stock Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related stocks with our FREE daily email newsletter.